Amino.Desk

ARA-290 (cibinetide)

Updated Nov 17, 2026 · Clinical review: pending

ARA-290, also called cibinetide, is a short peptide modeled on part of erythropoietin, the hormone that drives red blood cell production. It was tested for nerve pain in people with sarcoidosis. The small trials were encouraging, but it never reached Phase 3 and its development is inactive.

What it is

An 11-amino-acid peptide copied from one surface of erythropoietin. It was designed to switch on a tissue-repair receptor without raising red blood cell counts, which is the effect that makes erythropoietin itself risky to use for repair.

What the evidence shows

These are small, short trials. No Phase 3 trial was started, and the company that developed it has shut down. One drug database lists its clinical status as inactive.

Legal status

Reported dosing

No approved dose exists.

The dose-ranging trial gave 1 mg, 4 mg or 8 mg under the skin once a day for 28 days. Those are trial doses in a monitored study, not a recommendation.

Safety

Common questions

Is ARA-290 FDA-approved?

No. It was never submitted for approval, and its development is inactive.

What was ARA-290 tested for?

Mainly nerve pain from small fiber neuropathy in people with sarcoidosis, and also type 2 diabetes.

Does ARA-290 raise red blood cells like EPO?

It was designed not to. It is a fragment of erythropoietin built to act on a repair receptor only.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy